In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and this
nomenclature MAFLD was proposed to renovate its former name, non-alcoholic fatty liver …

Metabolic dysfunction–associated fatty liver disease (MAFLD) is nowadays considered the
liver manifestation of metabolic syndrome. Its prevalence is increasing worldwide in parallel …

Metabolic dysfunction–associated fatty liver disease (MAFLD) prevalence and incidence is
rising globally. It is associated with metabolic comorbidities, obesity, overweight, type 2 …

Despite the rising health burden of metabolic (dysfunction) associated fatty liver disease
(MAFLD), there are no approved pharmacotherapies for MAFLD currently. This situation led …

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from
nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on …

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the
most common chronic liver disease. MAFLD is a major risk factor for end-stage liver disease …

Metabolic dysfunction associated fatty liver disease (MAFLD) has been recently recognized
as a new global chronic liver disease entity with non-alcoholic fatty liver disease (NAFLD) …

Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty
liver disease, is the most widespread and emerging chronic liver disease worldwide, with …

Several studies have found that antifibrosis treatment for nonalcoholic fatty liver disease
(NAFLD) can cause a variety of side effects. No network meta-analysis (NMA) analyzes the …